Emerald Health Pharmaceuticals® is focused on developing novel, patented synthetic cannabinoid-derived drug candidates to treat diseases with unmet medical needs.

COMPANY HIGHLIGHTS

- Unique technology approach - developing new drugs that leverage the known benefits of cannabinoid interaction with the human endocannabinoid system (ECS) and modifying the molecule to target other disease-relevant receptors. These novel drugs may positively impact central nervous system (CNS), autoimmune, inflammatory, metabolic and fibrotic diseases.

- Composition of matter patents for series of 25 distinct molecules derived from the non-psychoactive cannabinoids, cannabidiol (CBD) and cannabigerol (CBG). The two lead product candidates are EHP-101 (derived from CBD) and EHP-102 (derived from CBG).

- EHP-101 is a first-in-class, potentially disease-modifying therapy for multiple sclerosis and systemic sclerosis, a form of scleroderma. A therapeutic margin (safe dose range), anti-inflammatory, neuroprotective, neuroregenerative, analgesic (pain relief), anti-proliferative (prevention of growth/spread), and to reduction of clinical signs and disease progression has been established in preclinical models.

- Phase I clinical study completed (safety established; full data forthcoming), with Phase 2 study initially for the treatment of systemic scleroderma underway in Australia and the initiation of this study in the United States later this year.

- Management and board have extensive life sciences industry expertise and experience. The management team each has at least 30 years of experience in life sciences and biotech and/or pharmaceutical product development.

- Multi-billion-dollar market potential in four initial indications: multiple sclerosis, systemic sclerosis, Parkinson’s disease and Huntington’s disease.

- Over 15 years of research and development published in leading journals such as Nature Scientific Reports, Biochemical Pharmacology and Journal of Neuroinflammation.

To find out more about Emerald Health Pharmaceuticals please contact: invest@emeraldpharma.life

PRODUCT PIPELINE

<table>
<thead>
<tr>
<th>Product Candidate</th>
<th>Indication</th>
<th>Proof of Concept</th>
<th>Formulation/Mfg</th>
<th>IND-enabling studies</th>
<th>Phase 1</th>
<th>Phase 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>EHP-101 (WE0048)</td>
<td>Multiple sclerosis, Systemic sclerosis (Scleroderma)</td>
<td>Orphan designation granted, US and EU</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EHP-102 (WE0052)</td>
<td>Parkinson’s disease, Huntington’s disease</td>
<td>Orphan designation granted, US and EU</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
GLOBAL MARKET VALUE & GROWTH RATE

Multiple Sclerosis (MS)
MS is a chronic inflammatory, degenerative, demyelinating disorder of the central nervous system (myelin is an essential insulating sheath around many nerve fibers, increasing the speed at which impulses are conducted). There are over 900,000 patients in 7 major markets. There are no effective disease-modifying drugs for progressive forms or therapies that re-myelinate damaged neurons. Market value: US $16.3B in 2016; expected to reach US $27.38B by 2025.

Parkinson’s Disease (PD)
PD is a chronic, progressive neurodegenerative disorder affecting nearly 10 million people worldwide. There is no current cure for PD. Initial treatments become less effective as the disease progresses. Market value: US $2.15B in 2016; expected to reach US $5.24B by 2025.

Systemic Sclerosis, a Form of Scleroderma (SSc)
SSc is a chronic systemic autoimmune disease causing fibrosis of skin and internal organs affecting fewer than 200,000 patients in the USA. It is classified as an orphan disease in the US and EU. There are no SSc-specific approved drugs on the market and current therapies not shown consistent benefit. Market value: US $1.68B in 2017; expected to reach US $3.66B by 2024.

Huntington’s Disease (HD)
A disorder that causes progressive breakdown of nerve cells and affects nearly 30,000 patients in the USA. There are no specific disease modifying therapies for HD. Market value: US $252.6M in 2014; expected to reach US $2.6B by 2024.

CLINICAL DEVELOPMENT

EHP-101: multiple sclerosis and systemic sclerosis
- Completed Phase 1 August 2019; data to be announced at a major conference; Phase 2 is underway.
- Granted orphan drug status by the U.S. FDA and EU EMA for systemic sclerosis indication; 7-year market exclusivity if approved, currently no sclerodema-specific approved drugs.
- Demonstrated potential disease-modifying benefits relating to demyelination and remyelination in multiple sclerosis models.

EHP-102: Parkinson’s disease and Huntington’s disease
- Completing formulation and manufacturing development; entering IND-enabling studies
- Granted orphan drug status by the U.S. FDA and EU EMA for Huntington’s disease; 7-year market exclusivity if approved, currently no approved drugs.
- Demonstrated potential to promote the regeneration of nerve cells, and protect against neuroinflammation and neurodegeneration in Parkinson’s disease and Huntington’s disease models.

LOOKING FORWARD

EHP-101
- Preparing initiation of Phase 2 human studies with initial Phase 2 data expected by the end of 2020.

EHP-102
- Preclinical proof-of-concept established for two indications. Formulation, manufacturing development and additional preclinical evaluations currently in process.

REFERENCES